Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation.
Wouter J PlattelLydia VisserArjan DiepstraAndor W J M GlaudemansMarcel NijlandTom van MeertenHanneke C Kluin-NelemansGustaaf W van ImhoffAnke van den BergPublished in: British journal of haematology (2020)
Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.
Keyphrases
- positron emission tomography
- hodgkin lymphoma
- computed tomography
- disease activity
- free survival
- pet ct
- rheumatoid arthritis
- systemic lupus erythematosus
- pet imaging
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- chronic kidney disease
- newly diagnosed
- high resolution
- ankylosing spondylitis
- photodynamic therapy
- clinical evaluation
- fluorescence imaging